Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGC-AD1 in Alzheimer's Disease Agitation
NCT05543681Phase 2Active, not recruiting
- Sponsor
- IGC Pharma
- Start
- Oct 2022
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of IGC-AD1 in agitation (2 arms), sponsored by IGC Pharma. Primary endpoint: Cohen-Mansfield Agitation Inventory (CMAI) score change at 6 weeks. Started Oct 2022; status: active, not recruiting.
02
Drugs
IGC-AD1
03
Conditions
agitation
Beyond the preview
Go deeper on NCT05543681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05543681.